Escherichia Coli.
C-type lectin domain family 2 member D, CLAX1, LLT11, OCIL.
Greater than 85.0% as determined by SDS-PAGE.
CLEC2D Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 155 amino acids (60-191 a.a.) and having a molecular mass of 17.7 kDa.
CLEC2D is fused to a 23 amino acid His tag at N-Terminus and purified by proprietary chromatographic techniques.
C-type lectin domain family 2 member D, CLAX1, LLT11, OCIL.
Escherichia Coli.
MGSSHHHHHH SSGLVPRGSH MGSRANCHQE PSVCLQAACP ESWIGFQRKC FYFSDDTKNW TSSQRFCDSQ DADLAQVESF QELNFLLRYK GPSDHWIGLS REQGQPWKWI NGTEWTRQFP ILGAGECAYL NDKGASSARH YTERKWICSK SDIHV
CLEC2D contains a transmembrane domain near the N-terminus and a C-type lectin-like extracellular domain . It is primarily expressed by B cells and monocytes in peripheral blood, antigen-presenting cells, activated lymphocytes, chondrocytes, and osteoblasts . The protein binds to high molecular weight sulfated glycosaminoglycans .
CLEC2D serves as a receptor for Killer cell lectin-like receptor B1 (KLRB1), protecting target cells against natural killer cell-mediated lysis . It inhibits osteoclast formation and bone resorption, thus playing a crucial role in bone metabolism . Additionally, CLEC2D modulates the release of interferon-gamma, an important cytokine in the immune response .
CLEC2D has been implicated in various physiological and pathological processes. Its ability to inhibit osteoclast formation and bone resorption makes it a potential target for treating bone-related diseases . Furthermore, its role in modulating immune responses suggests potential applications in immunotherapy .
Recombinant human CLEC2D is produced using recombinant DNA technology, which involves inserting the CLEC2D gene into a suitable expression system, such as 293E cells . The recombinant protein is then purified and used for various research and therapeutic purposes. It is available in different formulations and concentrations, with high purity and low endotoxin levels .